Results 11 to 20 of about 8,927 (183)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Active pulmonary tuberculosis in a patient with secukinumab treatment

Radiology Case Reports, 2023
Numerous investigations have documented active tuberculosis (TB) infection following biologic treatment. One of the most secure biologic medications for infections is secukinumab.
Cao Thanh Ngoc, MD, PhD, Bui Dang Khoa, MD, Huynh Khoi Nguyen, MD, Le Bao Le, MD, Dang Vinh Hiep, MD, PhD, Nguyen Minh Duc, MD   +5 more
doaj   +1 more source

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

Chinese Medical Journal, 2021
. Background:. There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jian-Zhong Zhang, Li-Shao Guo   +5 more
doaj   +1 more source

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

RMD Open, 2023
Background Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate.
Maxime Dougados, Pascal Claudepierre, Adeline Ruyssen-Witrand, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Julien Lucas, Emilie Desfleurs   +9 more
doaj   +1 more source

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

ACR Open Rheumatology, 2020
Objective Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years.
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, Susanne Rohrer, the MEASURE 3 study group   +11 more
doaj   +1 more source

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

Rheumatology and Therapy, 2019
Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States.
Prashanth Sunkureddi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Peter Hur, Reeti Joshi   +5 more
doaj   +1 more source

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

Rheumatology and Therapy, 2023
Introduction This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). Methods A total of 84 patients with oligoarticular PsA, defined as 1–4 tender joints and 1–4 swollen ...
Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, Bhumik Parikh, Philip J. Mease   +5 more
doaj   +1 more source

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Vaccines, 2022
Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis.
Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato, Giampiero Girolomoni   +5 more
doaj   +1 more source

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs

Mediators of Inflammation, 2020
Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the
Yu Zhou, Jinhui Ma, Juncheng Ge, Bailiang Wang, Debo Yue, Weiguo Wang   +5 more
doaj   +1 more source

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

RMD Open, 2018
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).Methods Following the 2-year core trial, eligible patients ...
Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop   +10 more
doaj   +1 more source